| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6190109 | Bulletin du Cancer | 2016 | 9 Pages |
Abstract
These results suggest that PFS/TTP is a useful early endpoint for patients with MBC who have undergone second- or third-line chemotherapy, especially for those who are HER2-positive.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Liya Liu, Feng Chen, Jinshun Zhao, Hao Yu,